6 November: FDA Committee does not recommend approval of Aducanumab
On 6 November., the US Food and Drug Administration (FDA)’s Peripheral and Central Nervous Systems Drugs Advisory Committee met to discuss the biologics license application and following these discussions, did not recommend approval of Aducanumab for the treatment of Alzheimer’s disease. This is however a non-binding recommendation and the FDA may decide not to follow it.
Read more »
|
10 November: AE organises 6th Alzheimer’s Association Academy
On 10 November, Alzheimer Europe hosted an online workshop as part of its 2020 Alzheimer’s Association Academy (AAA). This year's event is in three parts, on 10 and 24 November, and on 1 December. Topics include “Involving people with dementia in the development of and in research linked to medicinal products”; “Health data governance and data sharing: dementia research, patient privacy and EU policy”; and “Legal capacity and decision making”.
Read more »
|
17 November: Alzheimer’s Disease Data Initiative and AD workbench launched
On 17 November, a coalition of partners including the US Alzheimer’s Association, Gates Ventures and the Wellcome Trust launched the Alzheimer’s Disease Data Initiative (ADDI) and its AD Workbench. The AD Workbench and other ADDI initiatives aim to facilitate the sharing of dementia-related research data, empowering scientists and accelerating innovation in the AD field.
Read more »
|
23 November: PARADIGM project comes to a close
The IMI PARADIGM project officially ended this month, with a closing ceremony held for partners of the consortium, on 23 November. Representatives of the two co-leads, EFPIA and EPF, together with the project coordinator thanked everyone for their valuable contributions.
Read more »
|
|
|
|
|